Florida Senate - 2025 CS for SB 1360
By the Committee on Criminal Justice; and Senator Leek
591-02560-25 20251360c1
1 A bill to be entitled
2 An act relating to controlled substances; amending s.
3 893.03, F.S.; excepting from the Schedule I controlled
4 substance xylazine drug products approved by the
5 United States Food and Drug Administration for certain
6 use; amending s. 893.13, F.S.; providing criminal
7 penalties and requiring a mandatory minimum term of
8 imprisonment if a person sells, manufactures, or
9 delivers or possesses with intent to sell,
10 manufacture, or deliver xylazine; amending s. 893.135,
11 F.S.; creating the offense of trafficking in xylazine;
12 providing criminal penalties and requiring a mandatory
13 minimum term of imprisonment and fines based on the
14 quantity of the controlled substance involved in the
15 offense; providing an effective date.
16
17 Be It Enacted by the Legislature of the State of Florida:
18
19 Section 1. Paragraph (c) of subsection (1) of section
20 893.03, Florida Statutes, is amended to read:
21 893.03 Standards and schedules.—The substances enumerated
22 in this section are controlled by this chapter. The controlled
23 substances listed or to be listed in Schedules I, II, III, IV,
24 and V are included by whatever official, common, usual,
25 chemical, trade name, or class designated. The provisions of
26 this section shall not be construed to include within any of the
27 schedules contained in this section any excluded drugs listed
28 within the purview of 21 C.F.R. s. 1308.22, styled “Excluded
29 Substances”; 21 C.F.R. s. 1308.24, styled “Exempt Chemical
30 Preparations”; 21 C.F.R. s. 1308.32, styled “Exempted
31 Prescription Products”; or 21 C.F.R. s. 1308.34, styled “Exempt
32 Anabolic Steroid Products.”
33 (1) SCHEDULE I.—A substance in Schedule I has a high
34 potential for abuse and has no currently accepted medical use in
35 treatment in the United States and in its use under medical
36 supervision does not meet accepted safety standards. The
37 following substances are controlled in Schedule I:
38 (c) Unless specifically excepted or unless listed in
39 another schedule, any material, compound, mixture, or
40 preparation that contains any quantity of the following
41 hallucinogenic substances or that contains any of their salts,
42 isomers, including optical, positional, or geometric isomers,
43 homologues, nitrogen-heterocyclic analogs, esters, ethers, and
44 salts of isomers, homologues, nitrogen-heterocyclic analogs,
45 esters, or ethers, if the existence of such salts, isomers, and
46 salts of isomers is possible within the specific chemical
47 designation or class description:
48 1. Alpha-Ethyltryptamine.
49 2. 4-Methylaminorex (2-Amino-4-methyl-5-phenyl-2
50 oxazoline).
51 3. Aminorex (2-Amino-5-phenyl-2-oxazoline).
52 4. DOB (4-Bromo-2,5-dimethoxyamphetamine).
53 5. 2C-B (4-Bromo-2,5-dimethoxyphenethylamine).
54 6. Bufotenine.
55 7. Cannabis.
56 8. Cathinone.
57 9. DET (Diethyltryptamine).
58 10. 2,5-Dimethoxyamphetamine.
59 11. DOET (4-Ethyl-2,5-Dimethoxyamphetamine).
60 12. DMT (Dimethyltryptamine).
61 13. PCE (N-Ethyl-1-phenylcyclohexylamine) (Ethylamine
62 analog of phencyclidine).
63 14. JB-318 (N-Ethyl-3-piperidyl benzilate).
64 15. N-Ethylamphetamine.
65 16. Fenethylline.
66 17. 3,4-Methylenedioxy-N-hydroxyamphetamine.
67 18. Ibogaine.
68 19. LSD (Lysergic acid diethylamide).
69 20. Mescaline.
70 21. Methcathinone.
71 22. 5-Methoxy-3,4-methylenedioxyamphetamine.
72 23. PMA (4-Methoxyamphetamine).
73 24. PMMA (4-Methoxymethamphetamine).
74 25. DOM (4-Methyl-2,5-dimethoxyamphetamine).
75 26. MDEA (3,4-Methylenedioxy-N-ethylamphetamine).
76 27. MDA (3,4-Methylenedioxyamphetamine).
77 28. JB-336 (N-Methyl-3-piperidyl benzilate).
78 29. N,N-Dimethylamphetamine.
79 30. Parahexyl.
80 31. Peyote.
81 32. PCPY (N-(1-Phenylcyclohexyl)-pyrrolidine) (Pyrrolidine
82 analog of phencyclidine).
83 33. Psilocybin.
84 34. Psilocyn.
85 35. Salvia divinorum, except for any drug product approved
86 by the United States Food and Drug Administration which contains
87 Salvia divinorum or its isomers, esters, ethers, salts, and
88 salts of isomers, esters, and ethers, if the existence of such
89 isomers, esters, ethers, and salts is possible within the
90 specific chemical designation.
91 36. Salvinorin A, except for any drug product approved by
92 the United States Food and Drug Administration which contains
93 Salvinorin A or its isomers, esters, ethers, salts, and salts of
94 isomers, esters, and ethers, if the existence of such isomers,
95 esters, ethers, and salts is possible within the specific
96 chemical designation.
97 37. Xylazine, except for a xylazine animal drug product
98 approved by the United States Food and Drug Administration, the
99 use of which conforms to the approved application or is
100 authorized under 21 U.S.C. s. 360b(a)(4). The manufacture,
101 importation, distribution, prescribing, or sale of xylazine for
102 human use is not subject to this exception.
103 38. TCP (1-[1-(2-Thienyl)-cyclohexyl]-piperidine)
104 (Thiophene analog of phencyclidine).
105 39. 3,4,5-Trimethoxyamphetamine.
106 40. Methylone (3,4-Methylenedioxymethcathinone).
107 41. MDPV (3,4-Methylenedioxypyrovalerone).
108 42. Methylmethcathinone.
109 43. Methoxymethcathinone.
110 44. Fluoromethcathinone.
111 45. Methylethcathinone.
112 46. CP 47,497 (2-(3-Hydroxycyclohexyl)-5-(2-methyloctan-2
113 yl)phenol) and its dimethyloctyl (C8) homologue.
114 47. HU-210 [(6aR,10aR)-9-(Hydroxymethyl)-6,6-dimethyl-3-(2
115 methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol].
116 48. JWH-018 (1-Pentyl-3-(1-naphthoyl)indole).
117 49. JWH-073 (1-Butyl-3-(1-naphthoyl)indole).
118 50. JWH-200 (1-[2-(4-Morpholinyl)ethyl]-3-(1
119 naphthoyl)indole).
120 51. BZP (Benzylpiperazine).
121 52. Fluorophenylpiperazine.
122 53. Methylphenylpiperazine.
123 54. Chlorophenylpiperazine.
124 55. Methoxyphenylpiperazine.
125 56. DBZP (1,4-Dibenzylpiperazine).
126 57. TFMPP (Trifluoromethylphenylpiperazine).
127 58. MBDB (Methylbenzodioxolylbutanamine) or (3,4
128 Methylenedioxy-N-methylbutanamine).
129 59. 5-Hydroxy-AMT (5-Hydroxy-alpha-methyltryptamine).
130 60. 5-Hydroxy-N-methyltryptamine.
131 61. 5-MeO-MiPT (5-Methoxy-N-methyl-N-isopropyltryptamine).
132 62. 5-MeO-AMT (5-Methoxy-alpha-methyltryptamine).
133 63. Methyltryptamine.
134 64. 5-MeO-DMT (5-Methoxy-N,N-dimethyltryptamine).
135 65. 5-Me-DMT (5-Methyl-N,N-dimethyltryptamine).
136 66. Tyramine (4-Hydroxyphenethylamine).
137 67. 5-MeO-DiPT (5-Methoxy-N,N-Diisopropyltryptamine).
138 68. DiPT (N,N-Diisopropyltryptamine).
139 69. DPT (N,N-Dipropyltryptamine).
140 70. 4-Hydroxy-DiPT (4-Hydroxy-N,N-diisopropyltryptamine).
141 71. 5-MeO-DALT (5-Methoxy-N,N-Diallyltryptamine).
142 72. DOI (4-Iodo-2,5-dimethoxyamphetamine).
143 73. DOC (4-Chloro-2,5-dimethoxyamphetamine).
144 74. 2C-E (4-Ethyl-2,5-dimethoxyphenethylamine).
145 75. 2C-T-4 (4-Isopropylthio-2,5-dimethoxyphenethylamine).
146 76. 2C-C (4-Chloro-2,5-dimethoxyphenethylamine).
147 77. 2C-T (4-Methylthio-2,5-dimethoxyphenethylamine).
148 78. 2C-T-2 (4-Ethylthio-2,5-dimethoxyphenethylamine).
149 79. 2C-T-7 (4-(n)-Propylthio-2,5-dimethoxyphenethylamine).
150 80. 2C-I (4-Iodo-2,5-dimethoxyphenethylamine).
151 81. Butylone (3,4-Methylenedioxy-alpha
152 methylaminobutyrophenone).
153 82. Ethcathinone.
154 83. Ethylone (3,4-Methylenedioxy-N-ethylcathinone).
155 84. Naphyrone (Naphthylpyrovalerone).
156 85. Dimethylone (3,4-Methylenedioxy-N,N-dimethylcathinone).
157 86. 3,4-Methylenedioxy-N,N-diethylcathinone.
158 87. 3,4-Methylenedioxy-propiophenone.
159 88. 3,4-Methylenedioxy-alpha-bromopropiophenone.
160 89. 3,4-Methylenedioxy-propiophenone-2-oxime.
161 90. 3,4-Methylenedioxy-N-acetylcathinone.
162 91. 3,4-Methylenedioxy-N-acetylmethcathinone.
163 92. 3,4-Methylenedioxy-N-acetylethcathinone.
164 93. Bromomethcathinone.
165 94. Buphedrone (alpha-Methylamino-butyrophenone).
166 95. Eutylone (3,4-Methylenedioxy-alpha
167 ethylaminobutyrophenone).
168 96. Dimethylcathinone.
169 97. Dimethylmethcathinone.
170 98. Pentylone (3,4-Methylenedioxy-alpha
171 methylaminovalerophenone).
172 99. MDPPP (3,4-Methylenedioxy-alpha
173 pyrrolidinopropiophenone).
174 100. MDPBP (3,4-Methylenedioxy-alpha
175 pyrrolidinobutyrophenone).
176 101. MOPPP (Methoxy-alpha-pyrrolidinopropiophenone).
177 102. MPHP (Methyl-alpha-pyrrolidinohexanophenone).
178 103. BTCP (Benzothiophenylcyclohexylpiperidine) or BCP
179 (Benocyclidine).
180 104. F-MABP (Fluoromethylaminobutyrophenone).
181 105. MeO-PBP (Methoxypyrrolidinobutyrophenone).
182 106. Et-PBP (Ethylpyrrolidinobutyrophenone).
183 107. 3-Me-4-MeO-MCAT (3-Methyl-4-Methoxymethcathinone).
184 108. Me-EABP (Methylethylaminobutyrophenone).
185 109. Etizolam.
186 110. PPP (Pyrrolidinopropiophenone).
187 111. PBP (Pyrrolidinobutyrophenone).
188 112. PVP (Pyrrolidinovalerophenone) or
189 (Pyrrolidinopentiophenone).
190 113. MPPP (Methyl-alpha-pyrrolidinopropiophenone).
191 114. JWH-007 (1-Pentyl-2-methyl-3-(1-naphthoyl)indole).
192 115. JWH-015 (1-Propyl-2-methyl-3-(1-naphthoyl)indole).
193 116. JWH-019 (1-Hexyl-3-(1-naphthoyl)indole).
194 117. JWH-020 (1-Heptyl-3-(1-naphthoyl)indole).
195 118. JWH-072 (1-Propyl-3-(1-naphthoyl)indole).
196 119. JWH-081 (1-Pentyl-3-(4-methoxy-1-naphthoyl)indole).
197 120. JWH-122 (1-Pentyl-3-(4-methyl-1-naphthoyl)indole).
198 121. JWH-133 ((6aR,10aR)-6,6,9-Trimethyl-3-(2-methylpentan
199 2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromene).
200 122. JWH-175 (1-Pentyl-3-(1-naphthylmethyl)indole).
201 123. JWH-201 (1-Pentyl-3-(4-methoxyphenylacetyl)indole).
202 124. JWH-203 (1-Pentyl-3-(2-chlorophenylacetyl)indole).
203 125. JWH-210 (1-Pentyl-3-(4-ethyl-1-naphthoyl)indole).
204 126. JWH-250 (1-Pentyl-3-(2-methoxyphenylacetyl)indole).
205 127. JWH-251 (1-Pentyl-3-(2-methylphenylacetyl)indole).
206 128. JWH-302 (1-Pentyl-3-(3-methoxyphenylacetyl)indole).
207 129. JWH-398 (1-Pentyl-3-(4-chloro-1-naphthoyl)indole).
208 130. HU-211 ((6aS,10aS)-9-(Hydroxymethyl)-6,6-dimethyl-3
209 (2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1
210 ol).
211 131. HU-308 ([(1R,2R,5R)-2-[2,6-Dimethoxy-4-(2-methyloctan
212 2-yl)phenyl]-7,7-dimethyl-4-bicyclo[3.1.1]hept-3-enyl]
213 methanol).
214 132. HU-331 (3-Hydroxy-2-[(1R,6R)-3-methyl-6-(1
215 methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-2,5-cyclohexadiene
216 1,4-dione).
217 133. CB-13 (4-Pentyloxy-1-(1-naphthoyl)naphthalene).
218 134. CB-25 (N-Cyclopropyl-11-(3-hydroxy-5-pentylphenoxy)
219 undecanamide).
220 135. CB-52 (N-Cyclopropyl-11-(2-hexyl-5-hydroxyphenoxy)
221 undecanamide).
222 136. CP 55,940 (2-[3-Hydroxy-6-propanol-cyclohexyl]-5-(2
223 methyloctan-2-yl)phenol).
224 137. AM-694 (1-(5-Fluoropentyl)-3-(2-iodobenzoyl)indole).
225 138. AM-2201 (1-(5-Fluoropentyl)-3-(1-naphthoyl)indole).
226 139. RCS-4 (1-Pentyl-3-(4-methoxybenzoyl)indole).
227 140. RCS-8 (1-(2-Cyclohexylethyl)-3-(2
228 methoxyphenylacetyl)indole).
229 141. WIN55,212-2 ((R)-(+)-[2,3-Dihydro-5-methyl-3-(4
230 morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1
231 naphthalenylmethanone).
232 142. WIN55,212-3 ([(3S)-2,3-Dihydro-5-methyl-3-(4
233 morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1
234 naphthalenylmethanone).
235 143. Pentedrone (alpha-Methylaminovalerophenone).
236 144. Fluoroamphetamine.
237 145. Fluoromethamphetamine.
238 146. Methoxetamine.
239 147. Methiopropamine.
240 148. Methylbuphedrone (Methyl-alpha
241 methylaminobutyrophenone).
242 149. APB ((2-Aminopropyl)benzofuran).
243 150. APDB ((2-Aminopropyl)-2,3-dihydrobenzofuran).
244 151. UR-144 (1-Pentyl-3-(2,2,3,3
245 tetramethylcyclopropanoyl)indole).
246 152. XLR11 (1-(5-Fluoropentyl)-3-(2,2,3,3
247 tetramethylcyclopropanoyl)indole).
248 153. Chloro UR-144 (1-(Chloropentyl)-3-(2,2,3,3
249 tetramethylcyclopropanoyl)indole).
250 154. AKB48 (N-Adamant-1-yl 1-pentylindazole-3-carboxamide).
251 155. AM-2233(1-[(N-Methyl-2-piperidinyl)methyl]-3-(2
252 iodobenzoyl)indole).
253 156. STS-135 (N-Adamant-1-yl 1-(5-fluoropentyl)indole-3
254 carboxamide).
255 157. URB-597 ((3′-(Aminocarbonyl)[1,1′-biphenyl]-3-yl)
256 cyclohexylcarbamate).
257 158. URB-602 ([1,1′-Biphenyl]-3-yl-carbamic acid,
258 cyclohexyl ester).
259 159. URB-754 (6-Methyl-2-[(4-methylphenyl)amino]-1
260 benzoxazin-4-one).
261 160. 2C-D (4-Methyl-2,5-dimethoxyphenethylamine).
262 161. 2C-H (2,5-Dimethoxyphenethylamine).
263 162. 2C-N (4-Nitro-2,5-dimethoxyphenethylamine).
264 163. 2C-P (4-(n)-Propyl-2,5-dimethoxyphenethylamine).
265 164. 25I-NBOMe (4-Iodo-2,5-dimethoxy-[N-(2
266 methoxybenzyl)]phenethylamine).
267 165. MDMA (3,4-Methylenedioxymethamphetamine).
268 166. PB-22 (8-Quinolinyl 1-pentylindole-3-carboxylate).
269 167. Fluoro PB-22 (8-Quinolinyl 1-(fluoropentyl)indole-3
270 carboxylate).
271 168. BB-22 (8-Quinolinyl 1-(cyclohexylmethyl)indole-3
272 carboxylate).
273 169. Fluoro AKB48 (N-Adamant-1-yl 1-(fluoropentyl)indazole
274 3-carboxamide).
275 170. AB-PINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1
276 pentylindazole-3-carboxamide).
277 171. AB-FUBINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1
278 (4-fluorobenzyl)indazole-3-carboxamide).
279 172. ADB-PINACA (N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)
280 1-pentylindazole-3-carboxamide).
281 173. Fluoro ADBICA (N-(1-Amino-3,3-dimethyl-1-oxobutan-2
282 yl)-1-(fluoropentyl)indole-3-carboxamide).
283 174. 25B-NBOMe (4-Bromo-2,5-dimethoxy-[N-(2
284 methoxybenzyl)]phenethylamine).
285 175. 25C-NBOMe (4-Chloro-2,5-dimethoxy-[N-(2
286 methoxybenzyl)]phenethylamine).
287 176. AB-CHMINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1
288 (cyclohexylmethyl)indazole-3-carboxamide).
289 177. FUB-PB-22 (8-Quinolinyl 1-(4-fluorobenzyl)indole-3
290 carboxylate).
291 178. Fluoro-NNEI (N-Naphthalen-1-yl 1-(fluoropentyl)indole
292 3-carboxamide).
293 179. Fluoro-AMB (N-(1-Methoxy-3-methyl-1-oxobutan-2-yl)-1
294 (fluoropentyl)indazole-3-carboxamide).
295 180. THJ-2201 (1-(5-Fluoropentyl)-3-(1-naphthoyl)indazole).
296 181. AM-855 ((4aR,12bR)-8-Hexyl-2,5,5-trimethyl
297 1,4,4a,8,9,10,11,12b-octahydronaphtho[3,2-c]isochromen-12-ol).
298 182. AM-905 ((6aR,9R,10aR)-3-[(E)-Hept-1-enyl]-9
299 (hydroxymethyl)-6,6-dimethyl-6a,7,8,9,10,10a
300 hexahydrobenzo[c]chromen-1-ol).
301 183. AM-906 ((6aR,9R,10aR)-3-[(Z)-Hept-1-enyl]-9
302 (hydroxymethyl)-6,6-dimethyl-6a,7,8,9,10,10a
303 hexahydrobenzo[c]chromen-1-ol).
304 184. AM-2389 ((6aR,9R,10aR)-3-(1-Hexyl-cyclobut-1-yl)
305 6a,7,8,9,10,10a-hexahydro-6,6-dimethyl-6H-dibenzo[b,d]pyran-1,9
306 diol).
307 185. HU-243 ((6aR,8S,9S,10aR)-9-(Hydroxymethyl)-6,6
308 dimethyl-3-(2-methyloctan-2-yl)-8,9-ditritio-7,8,10,10a
309 tetrahydro-6aH-benzo[c]chromen-1-ol).
310 186. HU-336 ((6aR,10aR)-6,6,9-Trimethyl-3-pentyl
311 6a,7,10,10a-tetrahydro-1H-benzo[c]chromene-1,4(6H)-dione).
312 187. MAPB ((2-Methylaminopropyl)benzofuran).
313 188. 5-IT (2-(1H-Indol-5-yl)-1-methyl-ethylamine).
314 189. 6-IT (2-(1H-Indol-6-yl)-1-methyl-ethylamine).
315 190. Synthetic Cannabinoids.—Unless specifically excepted
316 or unless listed in another schedule or contained within a
317 pharmaceutical product approved by the United States Food and
318 Drug Administration, any material, compound, mixture, or
319 preparation that contains any quantity of a synthetic
320 cannabinoid found to be in any of the following chemical class
321 descriptions, or homologues, nitrogen-heterocyclic analogs,
322 isomers (including optical, positional, or geometric), esters,
323 ethers, salts, and salts of homologues, nitrogen-heterocyclic
324 analogs, isomers, esters, or ethers, whenever the existence of
325 such homologues, nitrogen-heterocyclic analogs, isomers, esters,
326 ethers, salts, and salts of isomers, esters, or ethers is
327 possible within the specific chemical class or designation.
328 Since nomenclature of these synthetically produced cannabinoids
329 is not internationally standardized and may continually evolve,
330 these structures or the compounds of these structures shall be
331 included under this subparagraph, regardless of their specific
332 numerical designation of atomic positions covered, if it can be
333 determined through a recognized method of scientific testing or
334 analysis that the substance contains properties that fit within
335 one or more of the following categories:
336 a. Tetrahydrocannabinols.—Any tetrahydrocannabinols
337 naturally contained in a plant of the genus Cannabis, the
338 synthetic equivalents of the substances contained in the plant
339 or in the resinous extracts of the genus Cannabis, or synthetic
340 substances, derivatives, and their isomers with similar chemical
341 structure and pharmacological activity, including, but not
342 limited to, Delta 9 tetrahydrocannabinols and their optical
343 isomers, Delta 8 tetrahydrocannabinols and their optical
344 isomers, Delta 6a,10a tetrahydrocannabinols and their optical
345 isomers, or any compound containing a tetrahydrobenzo[c]chromene
346 structure with substitution at either or both the 3-position or
347 9-position, with or without substitution at the 1-position with
348 hydroxyl or alkoxy groups, including, but not limited to:
349 (I) Tetrahydrocannabinol.
350 (II) HU-210 ((6aR,10aR)-9-(Hydroxymethyl)-6,6-dimethyl-3
351 (2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1
352 ol).
353 (III) HU-211 ((6aS,10aS)-9-(Hydroxymethyl)-6,6-dimethyl-3
354 (2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1
355 ol).
356 (IV) JWH-051 ((6aR,10aR)-9-(Hydroxymethyl)-6,6-dimethyl-3
357 (2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromene).
358 (V) JWH-133 ((6aR,10aR)-6,6,9-Trimethyl-3-(2-methylpentan
359 2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromene).
360 (VI) JWH-057 ((6aR,10aR)-6,6,9-Trimethyl-3-(2-methyloctan
361 2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromene).
362 (VII) JWH-359 ((6aR,10aR)-1-Methoxy-6,6,9-trimethyl-3-(2,3
363 dimethylpentan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromene).
364 (VIII) AM-087 ((6aR,10aR)-3-(2-Methyl-6-bromohex-2-yl)
365 6,6,9-trimethyl-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol).
366 (IX) AM-411 ((6aR,10aR)-3-(1-Adamantyl)-6,6,9-trimethyl
367 6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol).
368 (X) Parahexyl.
369 b. Naphthoylindoles, Naphthoylindazoles,
370 Naphthoylcarbazoles, Naphthylmethylindoles,
371 Naphthylmethylindazoles, and Naphthylmethylcarbazoles.—Any
372 compound containing a naphthoylindole, naphthoylindazole,
373 naphthoylcarbazole, naphthylmethylindole,
374 naphthylmethylindazole, or naphthylmethylcarbazole structure,
375 with or without substitution on the indole, indazole, or
376 carbazole ring to any extent, whether or not substituted on the
377 naphthyl ring to any extent, including, but not limited to:
378 (I) JWH-007 (1-Pentyl-2-methyl-3-(1-naphthoyl)indole).
379 (II) JWH-011 (1-(1-Methylhexyl)-2-methyl-3-(1
380 naphthoyl)indole).
381 (III) JWH-015 (1-Propyl-2-methyl-3-(1-naphthoyl)indole).
382 (IV) JWH-016 (1-Butyl-2-methyl-3-(1-naphthoyl)indole).
383 (V) JWH-018 (1-Pentyl-3-(1-naphthoyl)indole).
384 (VI) JWH-019 (1-Hexyl-3-(1-naphthoyl)indole).
385 (VII) JWH-020 (1-Heptyl-3-(1-naphthoyl)indole).
386 (VIII) JWH-022 (1-(4-Pentenyl)-3-(1-naphthoyl)indole).
387 (IX) JWH-071 (1-Ethyl-3-(1-naphthoyl)indole).
388 (X) JWH-072 (1-Propyl-3-(1-naphthoyl)indole).
389 (XI) JWH-073 (1-Butyl-3-(1-naphthoyl)indole).
390 (XII) JWH-080 (1-Butyl-3-(4-methoxy-1-naphthoyl)indole).
391 (XIII) JWH-081 (1-Pentyl-3-(4-methoxy-1-naphthoyl)indole).
392 (XIV) JWH-098 (1-Pentyl-2-methyl-3-(4-methoxy-1
393 naphthoyl)indole).
394 (XV) JWH-116 (1-Pentyl-2-ethyl-3-(1-naphthoyl)indole).
395 (XVI) JWH-122 (1-Pentyl-3-(4-methyl-1-naphthoyl)indole).
396 (XVII) JWH-149 (1-Pentyl-2-methyl-3-(4-methyl-1
397 naphthoyl)indole).
398 (XVIII) JWH-164 (1-Pentyl-3-(7-methoxy-1-naphthoyl)indole).
399 (XIX) JWH-175 (1-Pentyl-3-(1-naphthylmethyl)indole).
400 (XX) JWH-180 (1-Propyl-3-(4-propyl-1-naphthoyl)indole).
401 (XXI) JWH-182 (1-Pentyl-3-(4-propyl-1-naphthoyl)indole).
402 (XXII) JWH-184 (1-Pentyl-3-[(4-methyl)-1
403 naphthylmethyl]indole).
404 (XXIII) JWH-193 (1-[2-(4-Morpholinyl)ethyl]-3-(4-methyl-1
405 naphthoyl)indole).
406 (XXIV) JWH-198 (1-[2-(4-Morpholinyl)ethyl]-3-(4-methoxy-1
407 naphthoyl)indole).
408 (XXV) JWH-200 (1-[2-(4-Morpholinyl)ethyl]-3-(1
409 naphthoyl)indole).
410 (XXVI) JWH-210 (1-Pentyl-3-(4-ethyl-1-naphthoyl)indole).
411 (XXVII) JWH-387 (1-Pentyl-3-(4-bromo-1-naphthoyl)indole).
412 (XXVIII) JWH-398 (1-Pentyl-3-(4-chloro-1-naphthoyl)indole).
413 (XXIX) JWH-412 (1-Pentyl-3-(4-fluoro-1-naphthoyl)indole).
414 (XXX) JWH-424 (1-Pentyl-3-(8-bromo-1-naphthoyl)indole).
415 (XXXI) AM-1220 (1-[(1-Methyl-2-piperidinyl)methyl]-3-(1
416 naphthoyl)indole).
417 (XXXII) AM-1235 (1-(5-Fluoropentyl)-6-nitro-3-(1
418 naphthoyl)indole).
419 (XXXIII) AM-2201 (1-(5-Fluoropentyl)-3-(1
420 naphthoyl)indole).
421 (XXXIV) Chloro JWH-018 (1-(Chloropentyl)-3-(1
422 naphthoyl)indole).
423 (XXXV) Bromo JWH-018 (1-(Bromopentyl)-3-(1
424 naphthoyl)indole).
425 (XXXVI) AM-2232 (1-(4-Cyanobutyl)-3-(1-naphthoyl)indole).
426 (XXXVII) THJ-2201 (1-(5-Fluoropentyl)-3-(1
427 naphthoyl)indazole).
428 (XXXVIII) MAM-2201 (1-(5-Fluoropentyl)-3-(4-methyl-1
429 naphthoyl)indole).
430 (XXXIX) EAM-2201 (1-(5-Fluoropentyl)-3-(4-ethyl-1
431 naphthoyl)indole).
432 (XL) EG-018 (9-Pentyl-3-(1-naphthoyl)carbazole).
433 (XLI) EG-2201 (9-(5-Fluoropentyl)-3-(1
434 naphthoyl)carbazole).
435 c. Naphthoylpyrroles.—Any compound containing a
436 naphthoylpyrrole structure, with or without substitution on the
437 pyrrole ring to any extent, whether or not substituted on the
438 naphthyl ring to any extent, including, but not limited to:
439 (I) JWH-030 (1-Pentyl-3-(1-naphthoyl)pyrrole).
440 (II) JWH-031 (1-Hexyl-3-(1-naphthoyl)pyrrole).
441 (III) JWH-145 (1-Pentyl-5-phenyl-3-(1-naphthoyl)pyrrole).
442 (IV) JWH-146 (1-Heptyl-5-phenyl-3-(1-naphthoyl)pyrrole).
443 (V) JWH-147 (1-Hexyl-5-phenyl-3-(1-naphthoyl)pyrrole).
444 (VI) JWH-307 (1-Pentyl-5-(2-fluorophenyl)-3-(1
445 naphthoyl)pyrrole).
446 (VII) JWH-309 (1-Pentyl-5-(1-naphthalenyl)-3-(1
447 naphthoyl)pyrrole).
448 (VIII) JWH-368 (1-Pentyl-5-(3-fluorophenyl)-3-(1
449 naphthoyl)pyrrole).
450 (IX) JWH-369 (1-Pentyl-5-(2-chlorophenyl)-3-(1
451 naphthoyl)pyrrole).
452 (X) JWH-370 (1-Pentyl-5-(2-methylphenyl)-3-(1
453 naphthoyl)pyrrole).
454 d. Naphthylmethylenindenes.—Any compound containing a
455 naphthylmethylenindene structure, with or without substitution
456 at the 3-position of the indene ring to any extent, whether or
457 not substituted on the naphthyl ring to any extent, including,
458 but not limited to, JWH-176 (3-Pentyl-1
459 (naphthylmethylene)indene).
460 e. Phenylacetylindoles and Phenylacetylindazoles.—Any
461 compound containing a phenylacetylindole or phenylacetylindazole
462 structure, with or without substitution on the indole or
463 indazole ring to any extent, whether or not substituted on the
464 phenyl ring to any extent, including, but not limited to:
465 (I) JWH-167 (1-Pentyl-3-(phenylacetyl)indole).
466 (II) JWH-201 (1-Pentyl-3-(4-methoxyphenylacetyl)indole).
467 (III) JWH-203 (1-Pentyl-3-(2-chlorophenylacetyl)indole).
468 (IV) JWH-250 (1-Pentyl-3-(2-methoxyphenylacetyl)indole).
469 (V) JWH-251 (1-Pentyl-3-(2-methylphenylacetyl)indole).
470 (VI) JWH-302 (1-Pentyl-3-(3-methoxyphenylacetyl)indole).
471 (VII) Cannabipiperidiethanone.
472 (VIII) RCS-8 (1-(2-Cyclohexylethyl)-3-(2
473 methoxyphenylacetyl)indole).
474 f. Cyclohexylphenols.—Any compound containing a
475 cyclohexylphenol structure, with or without substitution at the
476 5-position of the phenolic ring to any extent, whether or not
477 substituted on the cyclohexyl ring to any extent, including, but
478 not limited to:
479 (I) CP 47,497 (2-(3-Hydroxycyclohexyl)-5-(2-methyloctan-2
480 yl)phenol).
481 (II) Cannabicyclohexanol (CP 47,497 dimethyloctyl (C8)
482 homologue).
483 (III) CP-55,940 (2-(3-Hydroxy-6-propanol-cyclohexyl)-5-(2
484 methyloctan-2-yl)phenol).
485 g. Benzoylindoles and Benzoylindazoles.—Any compound
486 containing a benzoylindole or benzoylindazole structure, with or
487 without substitution on the indole or indazole ring to any
488 extent, whether or not substituted on the phenyl ring to any
489 extent, including, but not limited to:
490 (I) AM-679 (1-Pentyl-3-(2-iodobenzoyl)indole).
491 (II) AM-694 (1-(5-Fluoropentyl)-3-(2-iodobenzoyl)indole).
492 (III) AM-1241 (1-[(N-Methyl-2-piperidinyl)methyl]-3-(2
493 iodo-5-nitrobenzoyl)indole).
494 (IV) Pravadoline (1-[2-(4-Morpholinyl)ethyl]-2-methyl-3-(4
495 methoxybenzoyl)indole).
496 (V) AM-2233 (1-[(N-Methyl-2-piperidinyl)methyl]-3-(2
497 iodobenzoyl)indole).
498 (VI) RCS-4 (1-Pentyl-3-(4-methoxybenzoyl)indole).
499 (VII) RCS-4 C4 homologue (1-Butyl-3-(4
500 methoxybenzoyl)indole).
501 (VIII) AM-630 (1-[2-(4-Morpholinyl)ethyl]-2-methyl-6-iodo
502 3-(4-methoxybenzoyl)indole).
503 h. Tetramethylcyclopropanoylindoles and
504 Tetramethylcyclopropanoylindazoles.—Any compound containing a
505 tetramethylcyclopropanoylindole or
506 tetramethylcyclopropanoylindazole structure, with or without
507 substitution on the indole or indazole ring to any extent,
508 whether or not substituted on the tetramethylcyclopropyl group
509 to any extent, including, but not limited to:
510 (I) UR-144 (1-Pentyl-3-(2,2,3,3
511 tetramethylcyclopropanoyl)indole).
512 (II) XLR11 (1-(5-Fluoropentyl)-3-(2,2,3,3
513 tetramethylcyclopropanoyl)indole).
514 (III) Chloro UR-144 (1-(Chloropentyl)-3-(2,2,3,3
515 tetramethylcyclopropanoyl)indole).
516 (IV) A-796,260 (1-[2-(4-Morpholinyl)ethyl]-3-(2,2,3,3
517 tetramethylcyclopropanoyl)indole).
518 (V) A-834,735 (1-[4-(Tetrahydropyranyl)methyl]-3-(2,2,3,3
519 tetramethylcyclopropanoyl)indole).
520 (VI) M-144 (1-(5-Fluoropentyl)-2-methyl-3-(2,2,3,3
521 tetramethylcyclopropanoyl)indole).
522 (VII) FUB-144 (1-(4-Fluorobenzyl)-3-(2,2,3,3
523 tetramethylcyclopropanoyl)indole).
524 (VIII) FAB-144 (1-(5-Fluoropentyl)-3-(2,2,3,3
525 tetramethylcyclopropanoyl)indazole).
526 (IX) XLR12 (1-(4,4,4-Trifluorobutyl)-3-(2,2,3,3
527 tetramethylcyclopropanoyl)indole).
528 (X) AB-005 (1-[(1-Methyl-2-piperidinyl)methyl]-3-(2,2,3,3
529 tetramethylcyclopropanoyl)indole).
530 i. Adamantoylindoles, Adamantoylindazoles, Adamantylindole
531 carboxamides, and Adamantylindazole carboxamides.—Any compound
532 containing an adamantoyl indole, adamantoyl indazole, adamantyl
533 indole carboxamide, or adamantyl indazole carboxamide structure,
534 with or without substitution on the indole or indazole ring to
535 any extent, whether or not substituted on the adamantyl ring to
536 any extent, including, but not limited to:
537 (I) AKB48 (N-Adamant-1-yl 1-pentylindazole-3-carboxamide).
538 (II) Fluoro AKB48 (N-Adamant-1-yl 1-(fluoropentyl)indazole
539 3-carboxamide).
540 (III) STS-135 (N-Adamant-1-yl 1-(5-fluoropentyl)indole-3
541 carboxamide).
542 (IV) AM-1248 (1-(1-Methylpiperidine)methyl-3-(1
543 adamantoyl)indole).
544 (V) AB-001 (1-Pentyl-3-(1-adamantoyl)indole).
545 (VI) APICA (N-Adamant-1-yl 1-pentylindole-3-carboxamide).
546 (VII) Fluoro AB-001 (1-(Fluoropentyl)-3-(1
547 adamantoyl)indole).
548 j. Quinolinylindolecarboxylates,
549 Quinolinylindazolecarboxylates, Quinolinylindolecarboxamides,
550 and Quinolinylindazolecarboxamides.—Any compound containing a
551 quinolinylindole carboxylate, quinolinylindazole carboxylate,
552 isoquinolinylindole carboxylate, isoquinolinylindazole
553 carboxylate, quinolinylindole carboxamide, quinolinylindazole
554 carboxamide, isoquinolinylindole carboxamide, or
555 isoquinolinylindazole carboxamide structure, with or without
556 substitution on the indole or indazole ring to any extent,
557 whether or not substituted on the quinoline or isoquinoline ring
558 to any extent, including, but not limited to:
559 (I) PB-22 (8-Quinolinyl 1-pentylindole-3-carboxylate).
560 (II) Fluoro PB-22 (8-Quinolinyl 1-(fluoropentyl)indole-3
561 carboxylate).
562 (III) BB-22 (8-Quinolinyl 1-(cyclohexylmethyl)indole-3
563 carboxylate).
564 (IV) FUB-PB-22 (8-Quinolinyl 1-(4-fluorobenzyl)indole-3
565 carboxylate).
566 (V) NPB-22 (8-Quinolinyl 1-pentylindazole-3-carboxylate).
567 (VI) Fluoro NPB-22 (8-Quinolinyl 1-(fluoropentyl)indazole
568 3-carboxylate).
569 (VII) FUB-NPB-22 (8-Quinolinyl 1-(4-fluorobenzyl)indazole
570 3-carboxylate).
571 (VIII) THJ (8-Quinolinyl 1-pentylindazole-3-carboxamide).
572 (IX) Fluoro THJ (8-Quinolinyl 1-(fluoropentyl)indazole-3
573 carboxamide).
574 k. Naphthylindolecarboxylates and
575 Naphthylindazolecarboxylates.—Any compound containing a
576 naphthylindole carboxylate or naphthylindazole carboxylate
577 structure, with or without substitution on the indole or
578 indazole ring to any extent, whether or not substituted on the
579 naphthyl ring to any extent, including, but not limited to:
580 (I) NM-2201 (1-Naphthalenyl 1-(5-fluoropentyl)indole-3
581 carboxylate).
582 (II) SDB-005 (1-Naphthalenyl 1-pentylindazole-3
583 carboxylate).
584 (III) Fluoro SDB-005 (1-Naphthalenyl 1
585 (fluoropentyl)indazole-3-carboxylate).
586 (IV) FDU-PB-22 (1-Naphthalenyl 1-(4-fluorobenzyl)indole-3
587 carboxylate).
588 (V) 3-CAF (2-Naphthalenyl 1-(2-fluorophenyl)indazole-3
589 carboxylate).
590 l. Naphthylindole carboxamides and Naphthylindazole
591 carboxamides.—Any compound containing a naphthylindole
592 carboxamide or naphthylindazole carboxamide structure, with or
593 without substitution on the indole or indazole ring to any
594 extent, whether or not substituted on the naphthyl ring to any
595 extent, including, but not limited to:
596 (I) NNEI (N-Naphthalen-1-yl 1-pentylindole-3-carboxamide).
597 (II) Fluoro-NNEI (N-Naphthalen-1-yl 1-(fluoropentyl)indole
598 3-carboxamide).
599 (III) Chloro-NNEI (N-Naphthalen-1-yl 1
600 (chloropentyl)indole-3-carboxamide).
601 (IV) MN-18 (N-Naphthalen-1-yl 1-pentylindazole-3
602 carboxamide).
603 (V) Fluoro MN-18 (N-Naphthalen-1-yl 1
604 (fluoropentyl)indazole-3-carboxamide).
605 m. Alkylcarbonyl indole carboxamides, Alkylcarbonyl
606 indazole carboxamides, Alkylcarbonyl indole carboxylates, and
607 Alkylcarbonyl indazole carboxylates.—Any compound containing an
608 alkylcarbonyl group, including 1-amino-3-methyl-1-oxobutan-2-yl,
609 1-methoxy-3-methyl-1-oxobutan-2-yl, 1-amino-1-oxo-3
610 phenylpropan-2-yl, 1-methoxy-1-oxo-3-phenylpropan-2-yl, with an
611 indole carboxamide, indazole carboxamide, indole carboxylate, or
612 indazole carboxylate, with or without substitution on the indole
613 or indazole ring to any extent, whether or not substituted on
614 the alkylcarbonyl group to any extent, including, but not
615 limited to:
616 (I) ADBICA, (N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1
617 pentylindole-3-carboxamide).
618 (II) Fluoro ADBICA (N-(1-Amino-3,3-dimethyl-1-oxobutan-2
619 yl)-1-(fluoropentyl)indole-3-carboxamide).
620 (III) Fluoro ABICA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1
621 (fluoropentyl)indole-3-carboxamide).
622 (IV) AB-PINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1
623 pentylindazole-3-carboxamide).
624 (V) Fluoro AB-PINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)
625 1-(fluoropentyl)indazole-3-carboxamide).
626 (VI) ADB-PINACA (N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)
627 1-pentylindazole-3-carboxamide).
628 (VII) Fluoro ADB-PINACA (N-(1-Amino-3,3-dimethyl-1
629 oxobutan-2-yl)-1-(fluoropentyl)indazole-3-carboxamide).
630 (VIII) AB-FUBINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1
631 (4-fluorobenzyl)indazole-3-carboxamide).
632 (IX) ADB-FUBINACA (N-(1-Amino-3,3-dimethyl-1-oxobutan-2
633 yl)-1-(4-fluorobenzyl)indazole-3-carboxamide).
634 (X) AB-CHMINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1
635 (cyclohexylmethyl)indazole-3-carboxamide).
636 (XI) MA-CHMINACA (N-(1-Methoxy-3-methyl-1-oxobutan-2-yl)-1
637 (cyclohexylmethyl)indazole-3-carboxamide).
638 (XII) MAB-CHMINACA (N-(1-Amino-3,3-dimethyl-1-oxobutan-2
639 yl)-1-(cyclohexylmethyl)indazole-3-carboxamide).
640 (XIII) AMB (N-(1-Methoxy-3-methyl-1-oxobutan-2-yl)-1
641 pentylindazole-3-carboxamide).
642 (XIV) Fluoro-AMB (N-(1-Methoxy-3-methyl-1-oxobutan-2-yl)-1
643 (fluoropentyl)indazole-3-carboxamide).
644 (XV) FUB-AMB (N-(1-Methoxy-3-methyl-1-oxobutan-2-yl)-1-(4
645 fluorobenzyl)indazole-3-carboxamide).
646 (XVI) MDMB-CHMINACA (N-(1-Methoxy-3,3-dimethyl-1-oxobutan
647 2-yl)-1-(cyclohexylmethyl)indazole-3-carboxamide).
648 (XVII) MDMB-FUBINACA (N-(1-Methoxy-3,3-dimethyl-1-oxobutan
649 2-yl)-1-(4-fluorobenzyl)indazole-3-carboxamide).
650 (XVIII) MDMB-CHMICA (N-(1-Methoxy-3,3-dimethyl-1-oxobutan
651 2-yl)-1-(cyclohexylmethyl)indole-3-carboxamide).
652 (XIX) PX-1 (N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1-(5
653 fluoropentyl)indole-3-carboxamide).
654 (XX) PX-2 (N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1-(5
655 fluoropentyl)indazole-3-carboxamide).
656 (XXI) PX-3 (N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1
657 (cyclohexylmethyl)indazole-3-carboxamide).
658 (XXII) PX-4 (N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1-(4
659 fluorobenzyl)indazole-3-carboxamide).
660 (XXIII) MO-CHMINACA (N-(1-Methoxy-3,3-dimethyl-1-oxobutan
661 2-yl)-1-(cyclohexylmethyl)indazole-3-carboxylate).
662 n. Cumylindolecarboxamides and Cumylindazolecarboxamides.
663 Any compound containing a N-(2-phenylpropan-2-yl) indole
664 carboxamide or N-(2-phenylpropan-2-yl) indazole carboxamide
665 structure, with or without substitution on the indole or
666 indazole ring to any extent, whether or not substituted on the
667 phenyl ring of the cumyl group to any extent, including, but not
668 limited to:
669 (I) CUMYL-PICA (N-(2-Phenylpropan-2-yl)-1-pentylindole-3
670 carboxamide).
671 (II) Fluoro CUMYL-PICA (N-(2-Phenylpropan-2-yl)-1
672 (fluoropentyl)indole-3-carboxamide).
673 o. Other Synthetic Cannabinoids.—Any material, compound,
674 mixture, or preparation that contains any quantity of a
675 Synthetic Cannabinoid, as described in sub-subparagraphs a.-n.:
676 (I) With or without modification or replacement of a
677 carbonyl, carboxamide, alkylene, alkyl, or carboxylate linkage
678 between either two core rings, or linkage between a core ring
679 and group structure, with or without the addition of a carbon or
680 replacement of a carbon;
681 (II) With or without replacement of a core ring or group
682 structure, whether or not substituted on the ring or group
683 structures to any extent; and
684 (III) Is a cannabinoid receptor agonist, unless
685 specifically excepted or unless listed in another schedule or
686 contained within a pharmaceutical product approved by the United
687 States Food and Drug Administration.
688 191. Substituted Cathinones.—Unless specifically excepted,
689 listed in another schedule, or contained within a pharmaceutical
690 product approved by the United States Food and Drug
691 Administration, any material, compound, mixture, or preparation,
692 including its salts, isomers, esters, or ethers, and salts of
693 isomers, esters, or ethers, whenever the existence of such salts
694 is possible within any of the following specific chemical
695 designations:
696 a. Any compound containing a 2-amino-1-phenyl-1-propanone
697 structure;
698 b. Any compound containing a 2-amino-1-naphthyl-1-propanone
699 structure; or
700 c. Any compound containing a 2-amino-1-thiophenyl-1
701 propanone structure,
702
703 whether or not the compound is further modified:
704 (I) With or without substitution on the ring system to any
705 extent with alkyl, alkylthio, thio, fused alkylenedioxy, alkoxy,
706 haloalkyl, hydroxyl, nitro, fused furan, fused benzofuran, fused
707 dihydrofuran, fused tetrahydropyran, fused alkyl ring, or halide
708 substituents;
709 (II) With or without substitution at the 3-propanone
710 position with an alkyl substituent or removal of the methyl
711 group at the 3-propanone position;
712 (III) With or without substitution at the 2-amino nitrogen
713 atom with alkyl, dialkyl, acetyl, or benzyl groups, whether or
714 not further substituted in the ring system; or
715 (IV) With or without inclusion of the 2-amino nitrogen atom
716 in a cyclic structure, including, but not limited to:
717 (A) Methcathinone.
718 (B) Ethcathinone.
719 (C) Methylone (3,4-Methylenedioxymethcathinone).
720 (D) 2,3-Methylenedioxymethcathinone.
721 (E) MDPV (3,4-Methylenedioxypyrovalerone).
722 (F) Methylmethcathinone.
723 (G) Methoxymethcathinone.
724 (H) Fluoromethcathinone.
725 (I) Methylethcathinone.
726 (J) Butylone (3,4-Methylenedioxy-alpha
727 methylaminobutyrophenone).
728 (K) Ethylone (3,4-Methylenedioxy-N-ethylcathinone).
729 (L) BMDP (3,4-Methylenedioxy-N-benzylcathinone).
730 (M) Naphyrone (Naphthylpyrovalerone).
731 (N) Bromomethcathinone.
732 (O) Buphedrone (alpha-Methylaminobutyrophenone).
733 (P) Eutylone (3,4-Methylenedioxy-alpha
734 ethylaminobutyrophenone).
735 (Q) Dimethylcathinone.
736 (R) Dimethylmethcathinone.
737 (S) Pentylone (3,4-Methylenedioxy-alpha
738 methylaminovalerophenone).
739 (T) Pentedrone (alpha-Methylaminovalerophenone).
740 (U) MDPPP (3,4-Methylenedioxy-alpha
741 pyrrolidinopropiophenone).
742 (V) MDPBP (3,4-Methylenedioxy-alpha
743 pyrrolidinobutyrophenone).
744 (W) MPPP (Methyl-alpha-pyrrolidinopropiophenone).
745 (X) PPP (Pyrrolidinopropiophenone).
746 (Y) PVP (Pyrrolidinovalerophenone) or
747 (Pyrrolidinopentiophenone).
748 (Z) MOPPP (Methoxy-alpha-pyrrolidinopropiophenone).
749 (AA) MPHP (Methyl-alpha-pyrrolidinohexanophenone).
750 (BB) F-MABP (Fluoromethylaminobutyrophenone).
751 (CC) Me-EABP (Methylethylaminobutyrophenone).
752 (DD) PBP (Pyrrolidinobutyrophenone).
753 (EE) MeO-PBP (Methoxypyrrolidinobutyrophenone).
754 (FF) Et-PBP (Ethylpyrrolidinobutyrophenone).
755 (GG) 3-Me-4-MeO-MCAT (3-Methyl-4-Methoxymethcathinone).
756 (HH) Dimethylone (3,4-Methylenedioxy-N,N
757 dimethylcathinone).
758 (II) 3,4-Methylenedioxy-N,N-diethylcathinone.
759 (JJ) 3,4-Methylenedioxy-N-acetylcathinone.
760 (KK) 3,4-Methylenedioxy-N-acetylmethcathinone.
761 (LL) 3,4-Methylenedioxy-N-acetylethcathinone.
762 (MM) Methylbuphedrone (Methyl-alpha
763 methylaminobutyrophenone).
764 (NN) Methyl-alpha-methylaminohexanophenone.
765 (OO) N-Ethyl-N-methylcathinone.
766 (PP) PHP (Pyrrolidinohexanophenone).
767 (QQ) PV8 (Pyrrolidinoheptanophenone).
768 (RR) Chloromethcathinone.
769 (SS) 4-Bromo-2,5-dimethoxy-alpha-aminoacetophenone.
770 192. Substituted Phenethylamines.—Unless specifically
771 excepted or unless listed in another schedule, or contained
772 within a pharmaceutical product approved by the United States
773 Food and Drug Administration, any material, compound, mixture,
774 or preparation, including its salts, isomers, esters, or ethers,
775 and salts of isomers, esters, or ethers, whenever the existence
776 of such salts is possible within any of the following specific
777 chemical designations, any compound containing a phenethylamine
778 structure, without a beta-keto group, and without a benzyl group
779 attached to the amine group, whether or not the compound is
780 further modified with or without substitution on the phenyl ring
781 to any extent with alkyl, alkylthio, nitro, alkoxy, thio,
782 halide, fused alkylenedioxy, fused furan, fused benzofuran,
783 fused dihydrofuran, or fused tetrahydropyran substituents,
784 whether or not further substituted on a ring to any extent, with
785 or without substitution at the alpha or beta position by any
786 alkyl substituent, with or without substitution at the nitrogen
787 atom, and with or without inclusion of the 2-amino nitrogen atom
788 in a cyclic structure, including, but not limited to:
789 a. 2C-B (4-Bromo-2,5-dimethoxyphenethylamine).
790 b. 2C-E (4-Ethyl-2,5-dimethoxyphenethylamine).
791 c. 2C-T-4 (4-Isopropylthio-2,5-dimethoxyphenethylamine).
792 d. 2C-C (4-Chloro-2,5-dimethoxyphenethylamine).
793 e. 2C-T (4-Methylthio-2,5-dimethoxyphenethylamine).
794 f. 2C-T-2 (4-Ethylthio-2,5-dimethoxyphenethylamine).
795 g. 2C-T-7 (4-(n)-Propylthio-2,5-dimethoxyphenethylamine).
796 h. 2C-I (4-Iodo-2,5-dimethoxyphenethylamine).
797 i. 2C-D (4-Methyl-2,5-dimethoxyphenethylamine).
798 j. 2C-H (2,5-Dimethoxyphenethylamine).
799 k. 2C-N (4-Nitro-2,5-dimethoxyphenethylamine).
800 l. 2C-P (4-(n)-Propyl-2,5-dimethoxyphenethylamine).
801 m. MDMA (3,4-Methylenedioxymethamphetamine).
802 n. MBDB (Methylbenzodioxolylbutanamine) or (3,4
803 Methylenedioxy-N-methylbutanamine).
804 o. MDA (3,4-Methylenedioxyamphetamine).
805 p. 2,5-Dimethoxyamphetamine.
806 q. Fluoroamphetamine.
807 r. Fluoromethamphetamine.
808 s. MDEA (3,4-Methylenedioxy-N-ethylamphetamine).
809 t. DOB (4-Bromo-2,5-dimethoxyamphetamine).
810 u. DOC (4-Chloro-2,5-dimethoxyamphetamine).
811 v. DOET (4-Ethyl-2,5-dimethoxyamphetamine).
812 w. DOI (4-Iodo-2,5-dimethoxyamphetamine).
813 x. DOM (4-Methyl-2,5-dimethoxyamphetamine).
814 y. PMA (4-Methoxyamphetamine).
815 z. N-Ethylamphetamine.
816 aa. 3,4-Methylenedioxy-N-hydroxyamphetamine.
817 bb. 5-Methoxy-3,4-methylenedioxyamphetamine.
818 cc. PMMA (4-Methoxymethamphetamine).
819 dd. N,N-Dimethylamphetamine.
820 ee. 3,4,5-Trimethoxyamphetamine.
821 ff. 4-APB (4-(2-Aminopropyl)benzofuran).
822 gg. 5-APB (5-(2-Aminopropyl)benzofuran).
823 hh. 6-APB (6-(2-Aminopropyl)benzofuran).
824 ii. 7-APB (7-(2-Aminopropyl)benzofuran).
825 jj. 4-APDB (4-(2-Aminopropyl)-2,3-dihydrobenzofuran).
826 kk. 5-APDB (5-(2-Aminopropyl)-2,3-dihydrobenzofuran).
827 ll. 6-APDB (6-(2-Aminopropyl)-2,3-dihydrobenzofuran).
828 mm. 7-APDB (7-(2-Aminopropyl)-2,3-dihydrobenzofuran).
829 nn. 4-MAPB (4-(2-Methylaminopropyl)benzofuran).
830 oo. 5-MAPB (5-(2-Methylaminopropyl)benzofuran).
831 pp. 6-MAPB (6-(2-Methylaminopropyl)benzofuran).
832 qq. 7-MAPB (7-(2-Methylaminopropyl)benzofuran).
833 rr. 5-EAPB (5-(2-Ethylaminopropyl)benzofuran).
834 ss. 5-MAPDB (5-(2-Methylaminopropyl)-2,3
835 dihydrobenzofuran),
836
837 which does not include phenethylamine, mescaline as described in
838 subparagraph 20., substituted cathinones as described in
839 subparagraph 191., N-Benzyl phenethylamine compounds as
840 described in subparagraph 193., or methamphetamine as described
841 in subparagraph (2)(c)5.
842 193. N-Benzyl Phenethylamine Compounds.—Unless specifically
843 excepted or unless listed in another schedule, or contained
844 within a pharmaceutical product approved by the United States
845 Food and Drug Administration, any material, compound, mixture,
846 or preparation, including its salts, isomers, esters, or ethers,
847 and salts of isomers, esters, or ethers, whenever the existence
848 of such salts is possible within any of the following specific
849 chemical designations, any compound containing a phenethylamine
850 structure without a beta-keto group, with substitution on the
851 nitrogen atom of the amino group with a benzyl substituent, with
852 or without substitution on the phenyl or benzyl ring to any
853 extent with alkyl, alkoxy, thio, alkylthio, halide, fused
854 alkylenedioxy, fused furan, fused benzofuran, or fused
855 tetrahydropyran substituents, whether or not further substituted
856 on a ring to any extent, with or without substitution at the
857 alpha position by any alkyl substituent, including, but not
858 limited to:
859 a. 25B-NBOMe (4-Bromo-2,5-dimethoxy-[N-(2
860 methoxybenzyl)]phenethylamine).
861 b. 25B-NBOH (4-Bromo-2,5-dimethoxy-[N-(2
862 hydroxybenzyl)]phenethylamine).
863 c. 25B-NBF (4-Bromo-2,5-dimethoxy-[N-(2
864 fluorobenzyl)]phenethylamine).
865 d. 25B-NBMD (4-Bromo-2,5-dimethoxy-[N-(2,3
866 methylenedioxybenzyl)]phenethylamine).
867 e. 25I-NBOMe (4-Iodo-2,5-dimethoxy-[N-(2
868 methoxybenzyl)]phenethylamine).
869 f. 25I-NBOH (4-Iodo-2,5-dimethoxy-[N-(2
870 hydroxybenzyl)]phenethylamine).
871 g. 25I-NBF (4-Iodo-2,5-dimethoxy-[N-(2
872 fluorobenzyl)]phenethylamine).
873 h. 25I-NBMD (4-Iodo-2,5-dimethoxy-[N-(2,3
874 methylenedioxybenzyl)]phenethylamine).
875 i. 25T2-NBOMe (4-Methylthio-2,5-dimethoxy-[N-(2
876 methoxybenzyl)]phenethylamine).
877 j. 25T4-NBOMe (4-Isopropylthio-2,5-dimethoxy-[N-(2
878 methoxybenzyl)]phenethylamine).
879 k. 25T7-NBOMe (4-(n)-Propylthio-2,5-dimethoxy-[N-(2
880 methoxybenzyl)]phenethylamine).
881 l. 25C-NBOMe (4-Chloro-2,5-dimethoxy-[N-(2
882 methoxybenzyl)]phenethylamine).
883 m. 25C-NBOH (4-Chloro-2,5-dimethoxy-[N-(2
884 hydroxybenzyl)]phenethylamine).
885 n. 25C-NBF (4-Chloro-2,5-dimethoxy-[N-(2
886 fluorobenzyl)]phenethylamine).
887 o. 25C-NBMD (4-Chloro-2,5-dimethoxy-[N-(2,3
888 methylenedioxybenzyl)]phenethylamine).
889 p. 25H-NBOMe (2,5-Dimethoxy-[N-(2
890 methoxybenzyl)]phenethylamine).
891 q. 25H-NBOH (2,5-Dimethoxy-[N-(2
892 hydroxybenzyl)]phenethylamine).
893 r. 25H-NBF (2,5-Dimethoxy-[N-(2
894 fluorobenzyl)]phenethylamine).
895 s. 25D-NBOMe (4-Methyl-2,5-dimethoxy-[N-(2
896 methoxybenzyl)]phenethylamine),
897
898 which does not include substituted cathinones as described in
899 subparagraph 191.
900 194. Substituted Tryptamines.—Unless specifically excepted
901 or unless listed in another schedule, or contained within a
902 pharmaceutical product approved by the United States Food and
903 Drug Administration, any material, compound, mixture, or
904 preparation containing a 2-(1H-indol-3-yl)ethanamine, for
905 example tryptamine, structure with or without mono- or di
906 substitution of the amine nitrogen with alkyl or alkenyl groups,
907 or by inclusion of the amino nitrogen atom in a cyclic
908 structure, whether or not substituted at the alpha position with
909 an alkyl group, whether or not substituted on the indole ring to
910 any extent with any alkyl, alkoxy, halo, hydroxyl, or acetoxy
911 groups, including, but not limited to:
912 a. Alpha-Ethyltryptamine.
913 b. Bufotenine.
914 c. DET (Diethyltryptamine).
915 d. DMT (Dimethyltryptamine).
916 e. MET (N-Methyl-N-ethyltryptamine).
917 f. DALT (N,N-Diallyltryptamine).
918 g. EiPT (N-Ethyl-N-isopropyltryptamine).
919 h. MiPT (N-Methyl-N-isopropyltryptamine).
920 i. 5-Hydroxy-AMT (5-Hydroxy-alpha-methyltryptamine).
921 j. 5-Hydroxy-N-methyltryptamine.
922 k. 5-MeO-MiPT (5-Methoxy-N-methyl-N-isopropyltryptamine).
923 l. 5-MeO-AMT (5-Methoxy-alpha-methyltryptamine).
924 m. Methyltryptamine.
925 n. 5-MeO-DMT (5-Methoxy-N,N-dimethyltryptamine).
926 o. 5-Me-DMT (5-Methyl-N,N-dimethyltryptamine).
927 p. 5-MeO-DiPT (5-Methoxy-N,N-Diisopropyltryptamine).
928 q. DiPT (N,N-Diisopropyltryptamine).
929 r. DPT (N,N-Dipropyltryptamine).
930 s. 4-Hydroxy-DiPT (4-Hydroxy-N,N-diisopropyltryptamine).
931 t. 5-MeO-DALT (5-Methoxy-N,N-Diallyltryptamine).
932 u. 4-AcO-DMT (4-Acetoxy-N,N-dimethyltryptamine).
933 v. 4-AcO-DiPT (4-Acetoxy-N,N-diisopropyltryptamine).
934 w. 4-Hydroxy-DET (4-Hydroxy-N,N-diethyltryptamine).
935 x. 4-Hydroxy-MET (4-Hydroxy-N-methyl-N-ethyltryptamine).
936 y. 4-Hydroxy-MiPT (4-Hydroxy-N-methyl-N
937 isopropyltryptamine).
938 z. Methyl-alpha-ethyltryptamine.
939 aa. Bromo-DALT (Bromo-N,N-diallyltryptamine),
940
941 which does not include tryptamine, psilocyn as described in
942 subparagraph 34., or psilocybin as described in subparagraph 33.
943 195. Substituted Phenylcyclohexylamines.—Unless
944 specifically excepted or unless listed in another schedule, or
945 contained within a pharmaceutical product approved by the United
946 States Food and Drug Administration, any material, compound,
947 mixture, or preparation containing a phenylcyclohexylamine
948 structure, with or without any substitution on the phenyl ring,
949 any substitution on the cyclohexyl ring, any replacement of the
950 phenyl ring with a thiophenyl or benzothiophenyl ring, with or
951 without substitution on the amine with alkyl, dialkyl, or alkoxy
952 substituents, inclusion of the nitrogen in a cyclic structure,
953 or any combination of the above, including, but not limited to:
954 a. BTCP (Benzothiophenylcyclohexylpiperidine) or BCP
955 (Benocyclidine).
956 b. PCE (N-Ethyl-1-phenylcyclohexylamine)(Ethylamine analog
957 of phencyclidine).
958 c. PCPY (N-(1-Phenylcyclohexyl)-pyrrolidine)(Pyrrolidine
959 analog of phencyclidine).
960 d. PCPr (Phenylcyclohexylpropylamine).
961 e. TCP (1-[1-(2-Thienyl)-cyclohexyl]-piperidine)(Thiophene
962 analog of phencyclidine).
963 f. PCEEA (Phenylcyclohexyl(ethoxyethylamine)).
964 g. PCMPA (Phenylcyclohexyl(methoxypropylamine)).
965 h. Methoxetamine.
966 i. 3-Methoxy-PCE ((3-Methoxyphenyl)cyclohexylethylamine).
967 j. Bromo-PCP ((Bromophenyl)cyclohexylpiperidine).
968 k. Chloro-PCP ((Chlorophenyl)cyclohexylpiperidine).
969 l. Fluoro-PCP ((Fluorophenyl)cyclohexylpiperidine).
970 m. Hydroxy-PCP ((Hydroxyphenyl)cyclohexylpiperidine).
971 n. Methoxy-PCP ((Methoxyphenyl)cyclohexylpiperidine).
972 o. Methyl-PCP ((Methylphenyl)cyclohexylpiperidine).
973 p. Nitro-PCP ((Nitrophenyl)cyclohexylpiperidine).
974 q. Oxo-PCP ((Oxophenyl)cyclohexylpiperidine).
975 r. Amino-PCP ((Aminophenyl)cyclohexylpiperidine).
976 196. W-15, 4-chloro-N-[1-(2-phenylethyl)-2
977 piperidinylidene]-benzenesulfonamide.
978 197. W-18, 4-chloro-N-[1-[2-(4-nitrophenyl)ethyl]-2
979 piperidinylidene]-benzenesulfonamide.
980 198. AH-7921, 3,4-dichloro-N-[[1
981 (dimethylamino)cyclohexyl]methyl]-benzamide.
982 199. U47700, trans-3,4-dichloro-N-[2
983 (dimethylamino)cyclohexyl]-N-methyl-benzamide.
984 200. MT-45, 1-cyclohexyl-4-(1,2-diphenylethyl)-piperazine,
985 dihydrochloride.
986 Section 2. Paragraph (i) of subsection (1) of section
987 893.13, Florida Statutes, is amended to read:
988 893.13 Prohibited acts; penalties.—
989 (1)
990 (i) Except as authorized by this chapter, a person commits
991 a felony of the first degree, punishable as provided in s.
992 775.082, s. 775.083, or s. 775.084, and must be sentenced to a
993 mandatory minimum term of imprisonment of 3 years, if:
994 1. The person sells, manufactures, or delivers, or
995 possesses with intent to sell, manufacture, or deliver, any of
996 the following:
997 a. Alfentanil, as described in s. 893.03(2)(b)1.;
998 b. Carfentanil, as described in s. 893.03(2)(b)6.;
999 c. Fentanyl, as described in s. 893.03(2)(b)9.;
1000 d. Sufentanil, as described in s. 893.03(2)(b)30.;
1001 e. A fentanyl derivative, as described in s.
1002 893.03(1)(a)63.;
1003 f. Xylazine, as described in s. 893.03(1)(c)37.;
1004 g. A controlled substance analog, as described in s.
1005 893.0356, of any substance described in sub-subparagraphs a.-f.
1006 sub-subparagraphs a.-e.; or
1007 h.g. A mixture containing any substance described in sub
1008 subparagraphs a.-g. sub-subparagraphs a.-f.; and
1009 2. The substance or mixture listed in subparagraph 1. is in
1010 a form that resembles, or is mixed, granulated, absorbed, spray
1011 dried, or aerosolized as or onto, coated on, in whole or in
1012 part, or solubilized with or into, a product, when such product
1013 or its packaging further has at least one of the following
1014 attributes:
1015 a. Resembles the trade dress of a branded food product,
1016 consumer food product, or logo food product;
1017 b. Incorporates an actual or fake registered copyright,
1018 service mark, or trademark;
1019 c. Resembles candy, cereal, a gummy, a vitamin, or a
1020 chewable product, such as a gum or gelatin-based product; or
1021 d. Contains a cartoon character imprint.
1022 Section 3. Paragraph (c) of subsection (1) of section
1023 893.135, Florida Statutes, is amended to read:
1024 893.135 Trafficking; mandatory sentences; suspension or
1025 reduction of sentences; conspiracy to engage in trafficking.—
1026 (1) Except as authorized in this chapter or in chapter 499
1027 and notwithstanding the provisions of s. 893.13:
1028 (c)1. A person who knowingly sells, purchases,
1029 manufactures, delivers, or brings into this state, or who is
1030 knowingly in actual or constructive possession of, 4 grams or
1031 more of any morphine, opium, hydromorphone, or any salt,
1032 derivative, isomer, or salt of an isomer thereof, including
1033 heroin, as described in s. 893.03(1)(b), (2)(a), (3)(c)3., or
1034 (3)(c)4., or 4 grams or more of any mixture containing any such
1035 substance, but less than 30 kilograms of such substance or
1036 mixture, commits a felony of the first degree, which felony
1037 shall be known as “trafficking in illegal drugs,” punishable as
1038 provided in s. 775.082, s. 775.083, or s. 775.084. If the
1039 quantity involved:
1040 a. Is 4 grams or more, but less than 14 grams, such person
1041 shall be sentenced to a mandatory minimum term of imprisonment
1042 of 3 years and shall be ordered to pay a fine of $50,000.
1043 b. Is 14 grams or more, but less than 28 grams, such person
1044 shall be sentenced to a mandatory minimum term of imprisonment
1045 of 15 years and shall be ordered to pay a fine of $100,000.
1046 c. Is 28 grams or more, but less than 30 kilograms, such
1047 person shall be sentenced to a mandatory minimum term of
1048 imprisonment of 25 years and shall be ordered to pay a fine of
1049 $500,000.
1050 2. A person who knowingly sells, purchases, manufactures,
1051 delivers, or brings into this state, or who is knowingly in
1052 actual or constructive possession of, 28 grams or more of
1053 hydrocodone, as described in s. 893.03(2)(a)1.k., codeine, as
1054 described in s. 893.03(2)(a)1.g., or any salt thereof, or 28
1055 grams or more of any mixture containing any such substance,
1056 commits a felony of the first degree, which felony shall be
1057 known as “trafficking in hydrocodone,” punishable as provided in
1058 s. 775.082, s. 775.083, or s. 775.084. If the quantity involved:
1059 a. Is 28 grams or more, but less than 50 grams, such person
1060 shall be sentenced to a mandatory minimum term of imprisonment
1061 of 3 years and shall be ordered to pay a fine of $50,000.
1062 b. Is 50 grams or more, but less than 100 grams, such
1063 person shall be sentenced to a mandatory minimum term of
1064 imprisonment of 7 years and shall be ordered to pay a fine of
1065 $100,000.
1066 c. Is 100 grams or more, but less than 300 grams, such
1067 person shall be sentenced to a mandatory minimum term of
1068 imprisonment of 15 years and shall be ordered to pay a fine of
1069 $500,000.
1070 d. Is 300 grams or more, but less than 30 kilograms, such
1071 person shall be sentenced to a mandatory minimum term of
1072 imprisonment of 25 years and shall be ordered to pay a fine of
1073 $750,000.
1074 3. A person who knowingly sells, purchases, manufactures,
1075 delivers, or brings into this state, or who is knowingly in
1076 actual or constructive possession of, 7 grams or more of
1077 oxycodone, as described in s. 893.03(2)(a)1.q., or any salt
1078 thereof, or 7 grams or more of any mixture containing any such
1079 substance, commits a felony of the first degree, which felony
1080 shall be known as “trafficking in oxycodone,” punishable as
1081 provided in s. 775.082, s. 775.083, or s. 775.084. If the
1082 quantity involved:
1083 a. Is 7 grams or more, but less than 14 grams, such person
1084 shall be sentenced to a mandatory minimum term of imprisonment
1085 of 3 years and shall be ordered to pay a fine of $50,000.
1086 b. Is 14 grams or more, but less than 25 grams, such person
1087 shall be sentenced to a mandatory minimum term of imprisonment
1088 of 7 years and shall be ordered to pay a fine of $100,000.
1089 c. Is 25 grams or more, but less than 100 grams, such
1090 person shall be sentenced to a mandatory minimum term of
1091 imprisonment of 15 years and shall be ordered to pay a fine of
1092 $500,000.
1093 d. Is 100 grams or more, but less than 30 kilograms, such
1094 person shall be sentenced to a mandatory minimum term of
1095 imprisonment of 25 years and shall be ordered to pay a fine of
1096 $750,000.
1097 4.a. A person who knowingly sells, purchases, manufactures,
1098 delivers, or brings into this state, or who is knowingly in
1099 actual or constructive possession of, 4 grams or more of:
1100 (I) Alfentanil, as described in s. 893.03(2)(b)1.;
1101 (II) Carfentanil, as described in s. 893.03(2)(b)6.;
1102 (III) Fentanyl, as described in s. 893.03(2)(b)9.;
1103 (IV) Sufentanil, as described in s. 893.03(2)(b)30.;
1104 (V) A fentanyl derivative, as described in s.
1105 893.03(1)(a)63.;
1106 (VI) A controlled substance analog, as described in s.
1107 893.0356, of any substance described in sub-sub-subparagraphs
1108 (I)-(V); or
1109 (VII) A mixture containing any substance described in sub
1110 sub-subparagraphs (I)-(VI),
1111
1112 commits a felony of the first degree, which felony shall be
1113 known as “trafficking in dangerous fentanyl or fentanyl
1114 analogues,” punishable as provided in s. 775.082, s. 775.083, or
1115 s. 775.084.
1116 b. If the quantity involved under sub-subparagraph a.:
1117 (I) Is 4 grams or more, but less than 14 grams, such person
1118 shall be sentenced to a mandatory minimum term of imprisonment
1119 of 7 years, and shall be ordered to pay a fine of $50,000.
1120 (II) Is 14 grams or more, but less than 28 grams, such
1121 person shall be sentenced to a mandatory minimum term of
1122 imprisonment of 20 years, and shall be ordered to pay a fine of
1123 $100,000.
1124 (III) Is 28 grams or more, such person shall be sentenced
1125 to a mandatory minimum term of imprisonment of 25 years, and
1126 shall be ordered to pay a fine of $500,000.
1127 c. A person 18 years of age or older who violates sub
1128 subparagraph a. by knowingly selling or delivering to a minor at
1129 least 4 grams of a substance or mixture listed in sub
1130 subparagraph a. shall be sentenced to a mandatory minimum term
1131 of not less than 25 years and not exceeding life imprisonment,
1132 and shall be ordered to pay a fine of $1 million if the
1133 substance or mixture listed in sub-subparagraph a. is in a form
1134 that resembles, or is mixed, granulated, absorbed, spray-dried,
1135 or aerosolized as or onto, coated on, in whole or in part, or
1136 solubilized with or into, a product, when such product or its
1137 packaging further has at least one of the following attributes:
1138 (I) Resembles the trade dress of a branded food product,
1139 consumer food product, or logo food product;
1140 (II) Incorporates an actual or fake registered copyright,
1141 service mark, or trademark;
1142 (III) Resembles candy, cereal, a gummy, a vitamin, or a
1143 chewable product, such as a gum or gelatin-based product; or
1144 (IV) Contains a cartoon character imprint.
1145 5. A person who knowingly sells, purchases, manufactures,
1146 delivers, or brings into this state, or who is knowingly in
1147 actual or constructive possession of, 30 kilograms or more of
1148 any morphine, opium, oxycodone, hydrocodone, codeine,
1149 hydromorphone, or any salt, derivative, isomer, or salt of an
1150 isomer thereof, including heroin, as described in s.
1151 893.03(1)(b), (2)(a), (3)(c)3., or (3)(c)4., or 30 kilograms or
1152 more of any mixture containing any such substance, commits the
1153 first degree felony of trafficking in illegal drugs. A person
1154 who has been convicted of the first degree felony of trafficking
1155 in illegal drugs under this subparagraph shall be punished by
1156 life imprisonment and is ineligible for any form of
1157 discretionary early release except pardon or executive clemency
1158 or conditional medical release under s. 947.149. However, if the
1159 court determines that, in addition to committing any act
1160 specified in this paragraph:
1161 a. The person intentionally killed an individual or
1162 counseled, commanded, induced, procured, or caused the
1163 intentional killing of an individual and such killing was the
1164 result; or
1165 b. The person’s conduct in committing that act led to a
1166 natural, though not inevitable, lethal result,
1167
1168 such person commits the capital felony of trafficking in illegal
1169 drugs, punishable as provided in ss. 775.082 and 921.142. A
1170 person sentenced for a capital felony under this paragraph shall
1171 also be sentenced to pay the maximum fine provided under
1172 subparagraph 1.
1173 6. A person who knowingly brings into this state 60
1174 kilograms or more of any morphine, opium, oxycodone,
1175 hydrocodone, codeine, hydromorphone, or any salt, derivative,
1176 isomer, or salt of an isomer thereof, including heroin, as
1177 described in s. 893.03(1)(b), (2)(a), (3)(c)3., or (3)(c)4., or
1178 60 kilograms or more of any mixture containing any such
1179 substance, and who knows that the probable result of such
1180 importation would be the death of a person, commits capital
1181 importation of illegal drugs, a capital felony punishable as
1182 provided in ss. 775.082 and 921.142. A person sentenced for a
1183 capital felony under this paragraph shall also be sentenced to
1184 pay the maximum fine provided under subparagraph 1.
1185 7. A person who knowingly sells, purchases, manufactures,
1186 delivers, or brings into this state, or who is knowingly in
1187 actual or constructive possession of, 4 grams or more of
1188 xylazine, as described in s. 893.03(1)(c)37., or any salt
1189 thereof, or 4 grams or more of any mixture containing any such
1190 substance, commits a felony of the first degree, which felony
1191 shall be known as “trafficking in xylazine,” punishable as
1192 provided in s. 775.082, s. 775.083, or s. 775.084. If the
1193 quantity involved:
1194 a. Is 4 grams or more, but less than 14 grams, such person
1195 shall be sentenced to a mandatory minimum term of imprisonment
1196 of 7 years and shall be ordered to pay a fine of $50,000.
1197 b. Is 14 grams or more, but less than 28 grams, such person
1198 shall be sentenced to a mandatory minimum term of imprisonment
1199 of 20 years and shall be ordered to pay a fine of $100,000.
1200 c. Is 28 grams or more, such person shall be sentenced to a
1201 mandatory minimum term of imprisonment of 25 years and shall be
1202 ordered to pay a fine of $500,000.
1203 Section 4. This act shall take effect October 1, 2025.